Home Featured Page 294

Featured

Latest

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Why Ayahuasca Is Miley Cyrus’ ‘Favorite’ Drug

Patent Combining Psychedelics with Cannabinoids Allowed by USPTO

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including...

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future...

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275...

Field Trip Health Ltd. Schedules Third Fiscal Quarter 2021 Financial Results...

Psyence Group Signs Collaboration Agreement with Leading Jamaican Psilocybin Retreat Provider...

NeonMind Submits Applications to Health Canada for Product Formulas to Support...

Nova Mentis Psilocybin Approved for Shipment to Italy

COMPASS Pathways expands its Discovery Center through new collaborations with world-leading...

1...293294295...297 Page 294 of 297

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But...

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Why Ayahuasca Is Miley Cyrus’ ‘Favorite’ Drug

Patent Combining Psychedelics with Cannabinoids Allowed by USPTO

Mind Cure Announces Closing of $23 Million Bought Deal Offering Including...

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future...

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275...

Field Trip Health Ltd. Schedules Third Fiscal Quarter 2021 Financial Results...

Psyence Group Signs Collaboration Agreement with Leading Jamaican Psilocybin Retreat Provider...

NeonMind Submits Applications to Health Canada for Product Formulas to Support...

Nova Mentis Psilocybin Approved for Shipment to Italy

COMPASS Pathways expands its Discovery Center through new collaborations with world-leading...

EDITOR PICKS

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But...

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY